Calcium dysregulation in Parkinson's disease

Brain

Volumn 136, Issue 7, 2013, Pages 2015-2016

  Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM; CALCIUM CHANNEL L TYPE; CALCIUM ION; MESSENGER RNA; SODIUM CALCIUM EXCHANGE PROTEIN; VOLTAGE GATED CALCIUM CHANNEL;

BRAIN; CALCIUM CELL LEVEL; CALCIUM CURRENT; CALCIUM HOMEOSTASIS; CELL LOSS; CELL MEMBRANE; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; EXTRACELLULAR CALCIUM; HUMAN; LYSOSOME; NERVE CELL; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE DEGENERATION; NOTE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SODIUM CALCIUM EXCHANGE; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING;

EID: 84879949218     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt180     Document Type: Note

References (16)

1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 2006; 5: 235-45
2. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: Dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-74
3. Davey GP, Bolanos JP. Peroxiredoxin 5 links mitochondrial redox signalling with calcium dynamics: Impact on Parkinson's disease. J Neurochem 2013; 125: 332-3
4. Goldberg JA, Guzman JN, Estep CM, Ilijic E, Kondapalli J, Sanchez-Padilla J, et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 2012; 15: 1414-21
5. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010; 468: 696-700
6. Hurley MJ, Brandon B, Gentleman SM, Dexter DT. Parkinson's disease is associated with altered expression of CaV1 channels and calcium binding proteins. Brain 2013
7. Hurley MJ, Dexter DT. Voltage-gated calcium channels and Parkinson's disease. Pharmacol Ther 2012; 133: 324-33
8. Kang S, Cooper G, Dunne SF, Dusel B, Luan CH, Surmeier DJ, et al. CaV1.3-selective L-Type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun 2012; 3: 1146
9. Kilpatrick BS, Eden ER, Schapira AH, Futter CE, Patel S. Direct mobilisation of lysosomal Ca2 + triggers complex Ca2 + signals. J Cell Sci 2013; 126 (Pt 1): 60-6
10. Mattson MP. Parkinson's disease: Don't mess with calcium. J Clin Invest 2012; 122: 1195-8
11. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 2012; 175: 627-35
12. Schapira AH. Mitochondrial diseases. Lancet 2012; 379: 1825-34
13. Selvaraj S, Sun Y, Watt JA, Wang S, Lei S, Birnbaumer L, et al. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 2012; 122: 1354-67
14. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007; 6: 933-8
15. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2013; 288: 10736-41
16. Tofaris GK. Lysosome-Dependent pathways as a unifying theme in Parkinson's disease. Mov Disord 2012; 27: 1364-9